Vimarsana
Biggest News Aggregation in the World

Page 11 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. - Vimarsana News

EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Issuer: Immunic, Inc. / Key word(s): Personnel Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. 27.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Strengthens Its Board of Directors with th...

EQS-News: Immunic, Inc.: Immunic to Participate in Investor and Scientific Conferences in May - Vimarsana News

EQS-News: Immunic, Inc.: Immunic to Participate in Investor and Scientific Conferences in May

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in May 26.04.2023 / 12:30 CET/CEST The issuer is solely responsible

Contrasting (RAMP) & Its Rivals | Daily Political - Vimarsana News

Contrasting (RAMP) & Its Rivals | Daily Political

Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The […]

Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Immunic, Inc. (NASDAQ:IMUX – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The […]

Source: wkrb13.com
Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis - Vimarsana News

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of...